Allobarbital
From Wikipedia, the free encyclopedia
 |
|
|
Allobarbital
|
|
| Systematic (IUPAC) name | |
| 5,5-diprop-2-enyl-1,3-diazinane-2,4,6-trione | |
| Identifiers | |
| CAS number | |
| ATC code | N05 |
| PubChem | |
| Chemical data | |
| Formula | C10H12N2O3 |
| Mol. mass | 208.214 g/mol |
| SMILES | & |
| Synonyms | 5,5-Diallylbarbituric acid, Allobarbital |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Allobarbital is a barbiturate derivative invented in 1912 by Ernst Preiswerk and Ernst Grether working for CIBA. It was used primarily as an anticonvulsant [1] although it has now largely been replaced by newer drugs with improved safety profiles. Other uses for allobarbital included as an adjutant to boost the activity of analgesic drugs, and use in the treatment of insomnia and anxiety.
Allobarbital was never particularly widely used compared to better known barbiturates such as phenobarbital and secobarbital, although it saw more use in some European countries such as Bulgaria and Slovakia,[2] and is still used in some countries in Asia, Africa and the Middle East.
[edit] References
- ^ Chocholova L, Radil-Weiss T. Effect of allobarbital on focal epilepsy in rats. Physiologia Bohemoslovaca. 1971;20(4):325-34.
- ^ Getova D, Georgiev V. GABA-ergic mechanisms in the anticonvulsive activity of newly-synthesized barbiturates. I. Effects of barbiturates on the convulsive action of GABA-antagonists. Acta Physiologica et Pharmacologica Bulgarica. 1987;13(3):43-50.
|
|||||
